{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:18:08Z","timestamp":1759342688963,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.revmed.2011.04.003","type":"journal-article","created":{"date-parts":[[2011,11,13]],"date-time":"2011-11-13T14:54:33Z","timestamp":1321196073000},"page":"742-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Canalopathies auto-immunes"],"prefix":"10.1016","volume":"32","author":[{"given":"M.","family":"Michaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Delrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Astudillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2011.04.003_bib0005","doi-asserted-by":"crossref","unstructured":"Didelot A, Honnorat J. Les syndromes neurologiques paran\u00e9oplasiques. Rev Med Interne 2011 doi:10.1016\/j.revmed.2010.09.007.","DOI":"10.1016\/j.revmed.2010.09.007"},{"key":"10.1016\/j.revmed.2011.04.003_bib0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0015","first-page":"400","article-title":"Treatment of autoimmune myasthenia","volume":"166","author":"Penisson-Besnier","year":"2010","journal-title":"Rev Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2011.04.003_bib0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2011.04.003_bib0030","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2011.04.003_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/08916939509001933","article-title":"Titin antibodies in patients with late onset myasthenia gravis: clinical correlations","volume":"20","author":"Skeie","year":"1995","journal-title":"Autoimmunity"},{"key":"10.1016\/j.revmed.2011.04.003_bib0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1468-1331.1999.650555.x","article-title":"EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis","volume":"6","author":"Somnier","year":"1999","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0050","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(00)00394-5","article-title":"Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations","volume":"111","author":"Romi","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-2004-829595","article-title":"Myasthenia gravis: management of myasthenic crisis and perioperative care","volume":"24","author":"Juel","year":"2004","journal-title":"Semin Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0070","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116\u00a0patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0085","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"issue":"201\u2013202","key":"10.1016\/j.revmed.2011.04.003_bib0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0095","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002:CD002275.","DOI":"10.1002\/14651858.CD002275"},{"key":"10.1016\/j.revmed.2011.04.003_bib0100","first-page":"939","article-title":"Long-term effects of plasma exchange in myasthenia. Results of a randomized study","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2011.04.003_bib0105","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.04.003_bib0110","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.revmed.2011.04.003_bib0120","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s004150070149","article-title":"Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis","volume":"247","author":"Yeh","year":"2000","journal-title":"J Neurol"},{"issue":"Pt 3","key":"10.1016\/j.revmed.2011.04.003_bib0125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome. A review of 50\u00a0cases","volume":"111","author":"O\u2019Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2011.04.003_bib0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddison","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.04.003_bib0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":"An improved diagnostic assay for Lambert-Eaton myasthenic syndrome","volume":"58","author":"Motomura","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2011.04.003_bib0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jneuroim.2005.03.020","article-title":"Antiglial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes","volume":"165","author":"Graus","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0145","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1\u00a0antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2011.04.003_bib0150","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/brain\/124.11.2223","article-title":"The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders","volume":"124","author":"Rees","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2011.04.003_bib0155","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2011.04.003_bib0160","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.42.10.1944","article-title":"Paraneoplastic cerebellar degeneration III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome","volume":"42","author":"Clouston","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2011.04.003_bib0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ana.10392","article-title":"Reduction of P\/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome","volume":"53","author":"Fukuda","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1212\/WNL.17.3.263","article-title":"Myotonia, myokymia, hyperhidrois and wasting of muscle","volume":"17","author":"Greenhouse","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2011.04.003_bib0175","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/jnnp.50.7.877","article-title":"Electrophysiological study on limb myokymia in three women","volume":"50","author":"Hosokawa","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2011.04.003_bib0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0404.1977.tb05647.x","article-title":"The syndrome of continuous muscle fiber activity. Evidence to suggest proximal neurogenic causation","volume":"55","author":"Irani","year":"1977","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.revmed.2011.04.003_bib0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archneur.1984.04050160057016","article-title":"Hereditary continuous muscle fiber activity","volume":"41","author":"McGuire","year":"1984","journal-title":"Arch Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1590\/S0004-282X1988000200009","article-title":"Isaacs syndrome: report of a case","volume":"46","author":"Teive","year":"1988","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.revmed.2011.04.003_bib0195","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/jnnp.37.11.1231","article-title":"The syndrome of \u201ccontinuous muscle-fibre activity\u201d cured: further studies","volume":"37","author":"Isaacs","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2011.04.003_bib0200","first-page":"1003","article-title":"Pseudo-myotonie","volume":"115","author":"Sigwald","year":"1966","journal-title":"Rev Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0205","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archneur.1979.00500440090022","article-title":"Continuous muscle fiber activity: a case with unusual clinical features","volume":"36","author":"Barron","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jnnp.46.3.241","article-title":"Syndromes of abnormal muscular activity: overlap between continuous muscle fibre activity and the stiff man syndrome","volume":"46","author":"Valli","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2011.04.003_bib0215","first-page":"282","article-title":"Continuous muscle fiber activity: Isaacs-Mertens\u2019 syndrome","volume":"53","author":"Magnuson","year":"1972","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.revmed.2011.04.003_bib0220","first-page":"178","article-title":"Systemic juvenile rheumatoid arthritis and associated Isaacs\u2019 syndrome","volume":"24","author":"Le Gars","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0225","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0035-3787(04)71010-3","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0230","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","article-title":"Phenotypic variants of autoimmune peripheral nerve hyperexcitability","volume":"125","author":"Hart","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2011.04.003_bib0235","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF01712058","article-title":"Neuromyotonia","volume":"43","author":"Mertens","year":"1965","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.revmed.2011.04.003_bib0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002826-198706000-00003","article-title":"Valproic acid in Isaacs-Mertens syndrome","volume":"10","author":"Vasilescu","year":"1987","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0245","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/jnnp.64.2.256","article-title":"Continuous muscle fibre activity: a case treated with acetazolamide","volume":"64","author":"Celebisoy","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2011.04.003_bib0250","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.clinph.2006.03.008","article-title":"Neuromuotonia","volume":"117","author":"Maddison","year":"2006","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2011.04.003_bib0260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1552-6569.2001.tb00011.x","article-title":"Limbic encephalitis investigated by 18FDG-PET and 3D MRI","volume":"11","author":"Kassubek","year":"2001","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.revmed.2011.04.003_bib0265","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.1097","article-title":"Potassium channel antibodies in two patients with reversible limbic encephalitis","volume":"50","author":"Buckley","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0270","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S0140-6736(03)12983-2","article-title":"Amnesia, cerebral atrophy, and autoimmunity","volume":"361","author":"Schott","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.04.003_bib0275","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.10713","article-title":"Voltage-gated potassium channel antibodies in limbic encephalitis","volume":"54","author":"Pozo-Rosich","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2011.04.003_bib0280","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1212\/01.wnl.0000187129.66353.13","article-title":"Serum antibodies in epilepsy and seizure-associated disorders","volume":"65","author":"McKnight","year":"2005","journal-title":"Neurology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311004930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311004930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:28:41Z","timestamp":1759336121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866311004930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0248866311004930"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2011.04.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canalopathies auto-immunes","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2011.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}